Dynavax Technologies Corp
Change company Symbol lookup
Select an option...
DVAX Dynavax Technologies Corp
GE General Electric Co
GTPBU Gores Technology Partners II Inc
IRBT iRobot Corp
NRG NRG Energy Inc
FRLAU Fortune Rise Acquisition Corp
BTBT Bit Digital Inc
RUMBW Rumble Equity Warrant Exp 16th Sept 2027 *W EXP 09/16/2027
RSLS ReShape Lifesciences Inc
BWA Borgwarner Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Postmarket

Last Trade
Delayed
$9.90
-0.03 (-0.30%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$9.93
Day's Change
-0.31 (-3.03%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
10.48
Day's Low
9.92
Volume
(Light)
Volume:
1,293,356

10-day average volume:
2,175,675
1,293,356

Evofem's stock jumps 30% after Supreme Court decision on Roe v. Wade

12:10 pm ET June 24, 2022 (MarketWatch)
Print

Shares of Evofem Biosciences Inc. (EVFM) soared 30.6% in trading on Friday, hours after the Supreme Court decision striking down Roe v. Wade was announced. Experts have speculated that the court's decision could lead to restrictions on birth control in the future although that was not included in Friday's decision. Evofem makes a non-hormonal gel that is used about an hour before sex to prevent pregnancy by controlling pH levels, which in turn lessens the mobility of sperm. It is prescribed by health care providers. "When women are denied safe, legal abortion, the importance of access to FDA-approved contraception is greater than it has ever been," Evfem CEO Saundra Pelletier told investors in May. Evofem's stock has declined 92.5% this year, while the broader S&P 500 is down 20.3%.

-Jaimy Lee

	

(END) Dow Jones Newswires

June 24, 2022 12:10 ET (16:10 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.